Erelzi (Subcutaneous)
Generic name:etanercept-szzs (subcutaneous route) [ ee-TAN-er-sept-- szzs ]
Drug classes:Antirheumatics, TNF alfa inhibitors
Medically reviewed by Drugs.com. Last updated on Mar 5, 2022.
Patients treated with etanercept products are at increased risk for infections, some progressing to serious infections leading to hospitalization or death. These infections have included bacterial sepsis, tuberculosis, invasive fungal and other opportunistic infections, including Legionella and Listeria. Evaluate for latent tuberculosis and treat if necessary prior to initiation of therapy. Discontinue etanercept-szzs if a serious infection or sepsis occurs during treatment. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept products .
Commonly used brand name(s)
In the U.S.
- Erelzi
Pharmacologic Class: Etanercept
Uses for Erelzi
Etanercept-szzs injection is used alone or with other medicines (eg, methotrexate) to reduce signs and symptoms of rheumatoid arthritis or psoriatic arthritis, such as joint swelling, pain, tiredness, and duration of morning stiffness. It may also be used to treat a condition known as ankylosing spondylitis.
Etanercept-szzs injection is also used to treat polyarticular juvenile idiopathic arthritis. It is also used to treat moderate to severe plaque psoriasis in patients who may benefit from receiving phototherapy (ultraviolet light treatment) or other treatments.
This medicine is available only with your doctor's prescription.
Before using Erelzi
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of etanercept-szzs injection in children with juvenile idiopathic arthritis younger than 2 years of age and in children with psoriasis younger than 4 years of age. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of etanercept-szzs injection in the elderly. However, elderly patients are more likely to have infections, which may require caution in patients receiving etanercept-szzs.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding..
